Side-by-side comparison
Gilead Sciences vs Merck & Co.
As of Sep 25, 2026, P/S is 6.1x for Gilead Sciences vs 5.5x for Merck & Co.; revenue growth is 5.5% for Gilead Sciences vs 4.6% for Merck & Co.; net margin is -10.6% for Gilead Sciences vs 4.8% for Merck & Co.; debt/equity is 2.01 for Gilead Sciences vs 1.22 for Merck & Co..
Key metrics
| Metric | GILD | MRK |
|---|---|---|
| Price | $150.93 | $148.78 |
| Market cap | $187.15B | $367.07B |
| P/E | — | 119.0x (#1) |
| P/S | 6.1x (#2) | 5.5x (#1) |
| Revenue growth | 5.5% (#1) | 4.6% (#2) |
| Operating margin | -8.2% (#1) | — |
| Net margin | -10.6% (#2) | 4.8% (#1) |
| Debt / equity | 2.01 (#2) | 1.22 (#1) |
| 1-year return | +34.6% (#2) | +89.4% (#1) |
| Research score | 42/100 (#2) | 51/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General